BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events
ME Staff 8-k
BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other EventsItem 8.01 Other Events
On July5, 2017, BeiGene,Ltd. (the “Company”) issued a press release announcing the dosing of the first patient in a pivotal clinical trial of BGB-A317, an investigational humanized monoclonal antibody, in China designed to investigate the efficacy and safety of BGB-A317 in patients with previously treated, PD-L1-positive, locally advanced or metastatic urothelial cancer. The full text of the Company’s press release is filed as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits
(d) Exhibits.
ExhibitNo.
Description
99.1
Press Release issued on July5, 2017
***
BeiGene, Ltd. ExhibitEX-99.1 2 a17-16066_1ex99d1.htm EX-99.1 Exhibit 99.1 BeiGene,…To view the full exhibit click here About BEIGENE,LTD. (NASDAQ:BGNE) BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers. BEIGENE,LTD. (NASDAQ:BGNE) Recent Trading Information BEIGENE,LTD. (NASDAQ:BGNE) closed its last trading session up +9.36 at 54.36 with 211,606 shares trading hands.